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Background: Allogeneic hematopoietic stem cell transplantation
(aHSCT) is being used with increasing success in pediatric patients
to treat a variety of malignant and non-malignant diseases. However,
pulmonary complications account for meaningful morbidity and
mortality in aHSCT recipients.
Objective: We assessed the prevalence of pre and post-aHSCT
lung function abnormalities at Riley Hospital for Children to
identify risk factors that may predict post-aHSCT morbidity and
mortality.
Methods: We retrospectively reviewed the medical records of 46
patients, aged 5–21 years, who received aHSCT between 1 January
2001 and 31 December 2006. Forty-one patients, who underwent
pulmonary function tests (PFTs) both before and after aHSCT,
were eligible for analysis. Pertinent demographic, aHSCT and
treatment-related data, and baseline (pre-aHSCT), 1 and 2-year
post-aHSCT PFT data were collected. Forced expiratory volume
in 1 second (FEV1), forced vital capacity (FVC), residual volume
(RV), total lung capacity (TLC), and diffusion capacity for carbon
monoxide adjusted for alveolar volume and hemoglobin (DLCOa/
VA) were determined as percentage predicted for age, sex, and
length matched controls. Analyses included logistic regression,
with and without generalized estimating equations, and mixed
effects models.
Results: Significantly lower FEV1, FVC, TLC, but similar
FEV1/FVC was noted at 1 year post-aHSCT. However, these find-
ings were no longer significant at 2 years post-aHSCT. Low base-
line DLCOa/VA was associated with death. Refractory disease
before aHSCT was significantly associated with lower FEV1,
FVC, and TLC after aHSCT. Age, CMV status, previous pulmo-
nary-toxic chemotherapy, and aHSCT conditioning were not sig-
nificantly associated with outcomes. Acute and chronic graft
versus host disease (GVHD) was significantly associated with
higher post-aHSCT RV.
Conclusions: Obstructive lung patterns contribute to post-
aHSCT morbidity, especially in the first year following aHSCT.
Low baseline DLCOa/VA was a risk factor for mortality. Pediatric pa-
tients who have evidence of acute and chronic GVHD are more
likely to have associated obstructive lung disease which suggests
that therapeutic intervention may prevent morbidity. Further
prospective studies are needed to assess the utility of long-term respi-
ratory monitoring in pediatric aHSCT recipients.224
MATCHED UNRELATED BONE MARROW TRANSPLANT FOR OMENN SYN-
DROME
Nahum, A., Reid, B., Grunebaum, E., Roifman, C.M. The Hospital for
Sick Children
Little information is currently available on the outcome and the
long term restoration of immune function in infants with Omenn
syndrome (OS) treated with bone marrow transplantation (BMT).
We prospectively followed patients with OS who received matched
unrelated donor bone marrow transplantation at our center. En-
graftment, immune reconstitution and transplant-related complica-
tions were recorded. Humoral and cellular immunity were
evaluated. Six patients with OS were diagnosed at a mean age of
4.6 months. Two had mutations in the RMRP gene, one had mu-
tations in DNA Ligase 4, while the rest genotype could not be de-
termined. They received a matched unrelated donor bone marrowtransplantation as the first BMT at the mean age of 9.4 months. All
six patients are alive and well at a mean 95 months after transplant.
All patients have evidence of full hemopoetic engraftment and ro-
bust immune reconstitution. Three out of six patients developed
GvHD of Grade II or more, which was reversed in all patients
by using short courses of high dose methylprednisolone. We
have shown here that matched unrelated donor bone marrow trans-
plantation is highly effective in curing patients with Omenn syn-
drome regardless of their genotype. This mode of treatment
should be preferred for patients with OS when a related identical
donor is not available.225
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Background: Patients undergoing chemotherapy and radiation
have been shown to be in a state of oxidative stress. Acetaminophen
is known to cause depletion of glutathione, a key component of the
body’s antioxidant defense mechanism. Acetaminophen is also
known to cause liver toxicity and recently has been linked with sever-
ity of lung disease in asthmatics and alcoholics. Therefore, we ques-
tioned whether acetaminophen usage in patients undergoing
hematopoetic stem cell transplant (HSCT) could place them at
risk for organ dysfunction.
Methods: A retrospective chart review was performed on all pa-
tients undergoing HSCT at the Children’s Hospital of Wisconsin
between January 1, 1995–January 1, 2005. Cumulative dosage of
acetaminophen in mg/ kg was calculated on all patients during con-
ditioning and the first 14 days after stem cell infusion. Charts were
reviewed for evidence of veno-occlusive disease (VOD) of the liver
as diagnosed by the attending HSCT physician, respiratory insuffi-
ciency as defined by requirement of $2 l/min of nasal cannula oxy-
gen, and renal insufficiency as defined by doubling of the serum
creatinine. Statistical analysis was done using the unpaired student
t-test.
Results: Preliminary analysis found 330 patients who underwent
HSCT during the study time period. There was a statistically signif-
icant difference in the mean acetaminophen dose used in patient who
developed VOD (303 mg/kg) in comparison to those who did not
(213 mg/kg) with p5 .036. The difference in acetaminophen dosage
between those who developed renal insufficiency (278mg/kg) com-
pared to those who did not (210 mg/kg) was also significant (p 5
.028). The most significant difference was seen when comparing
patients who did (277 mg/kg) and did not (202 mg/kg) develop respi-
ratory insufficiency (p 5 .0019). Also of interest in our data set was
that of the 80 patients who developed respiratory insufficiency (re-
quirement of $2 l/min nasal cannula oxygen), 55 (69%) went on
to require some form of mechanical ventilation. The relative risk
of death in this population was 2.04 (95% CI 1.70–2.45).
Conclusion: This patient population is highly complex with mul-
tiple confounding variables. It is still unclear if acetaminophen is
a cause or marker of severity of illness in pediatric HSCT patients.
However, avoidance of frequent acetaminophen dosing may be ben-
eficial whenever possible.226
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Background: Osteosarcoma is the most common pediatric bone
tumor. Despite aggressive multimodal therapy survival rates for pa-
tients with metastatic or recurrent disease remain poor. New
